Collegium Pharmaceutical Ends Grünenthal Nucynta U.S. License After $17 Million Settlement

Collegium Pharmaceutical settled with Grünenthal for $17M, ending their U.S. license agreement for Nucynta products and resolving pending patent litigation. The deal terminates the 2015 license and 2020 consent agreement, with Collegium gaining certain patents and eliminating future royalties.

Original reporting
Published Oct 19, 2026, 8:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 8:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Collegium Pharmaceutical Ends Grünenthal Nucynta U.S. License After $17 Million Settlement — source image
Decision brief

The 30-second read

$COLLBullishMed
01

Why it matters

The deal eliminates royalty obligations and grants patents to Collegium, likely improving profitability and reducing legal risk.

02

Market read

A material legal settlement for a mid‑cap pharma firm, potentially moving the stock on the news.

03

What to watch

Potential future litigation risk if Grünenthal challenges the patent assignments.

Relevance 6/10Novelty 7/10Timing: post‑filing today

Background

Collegium Pharmaceutical (COLL) announced a settlement with Grünenthal, ending a long‑standing licensing agreement for the opioid Nucynta and paying $17 million.

Company-level read

Ticker impact

$COLLBullishHigh confidence
Context

Collegium Pharmaceutical settled a $17M dispute, terminated its U.S. Nucynta license and received patent assignments.

Expected impact

likely upward pressure as the market prices in reduced royalty costs and stronger patent position

Evidence & confidence

Removal of ongoing royalty payments and acquisition of patents are material to earnings and cash flow.

Market effects

May affect other generic opioid manufacturers by altering competitive dynamics for Nucynta equivalents.

Limited to U.S. pharmaceutical market where the license was terminated.

Low; impact confined to Collegium and its niche product line.

Counterpoint

The settlement could signal deeper issues with Nucynta's market potential, suggesting a possible downside.

Key entities

  • Collegium Pharmaceutical

    U.S. listed pharmaceutical company (ticker COLL).

  • Grünenthal

    German pharmaceutical firm, original licensor of Nucynta.

Related articles

$COLLMedAI 8/10

Collegium Pharmaceutical Earnings Call Highlights ADHD Growth

Collegium Pharmaceutical (COLL) reported Q3 record revenue of $216.3M, up 3% YoY, driven by ADHD products (36% of total revenue). Jornay PM grew 24% YoY to $52M-$59.5M, while Azstarys saw 2% prescription growth. Pain portfolio revenue declined 9% YoY. Adjusted EBITDA fell 9% to $121.6M. The company reaffirmed 2026 guidance, expecting flat adjusted EBITDA.

$COLLMed

Jefferies cuts Collegium Pharmaceutical stock price target on pain business concerns

Jefferies reduced its price target for Collegium Pharmaceutical (COLL) to $35 from $51, citing concerns about its pain business. The stock is down 45.66% year-to-date. The company reported Q3 2026 earnings, beating EPS estimates but meeting revenue expectations. Management plans to continue share buybacks and deleverage. Jefferies expects modest EBITDA growth by 2027, with ADHD business growth offsetting pain segment declines.

$COLLMed

Collegium (COLL) Q3 2026 Earnings Call Transcript

Collegium (COLL) reported Q3 2026 net revenue of $216.3M, up 3% YoY. Jornay PM prescriptions grew 16% YoY, generating $59.5M in revenue. Azstarys revenue was $26.5M, with prescriptions up nearly 2% YoY. The company reaffirmed full-year guidance and announced a $50M share repurchase program.

$COLLMed

Collegium Pharmaceutical Q3 Earnings Call Highlights

Collegium Pharmaceutical reported Q3 revenue of $138M from its pain portfolio, with BELBUCA sales at $57.7M, XTAMPZA ER at $45.8M, and NUCYNTA at $30.8M. The company expects AZSTARYS prescription growth to accelerate in 2027 and reaffirmed its 2026 revenue forecast of $825M-$855M. It plans a $50M share repurchase and has $100M remaining under its authorization.